We are live on ! Find out more
PHP

Parkman Healthcare Partners Portfolio holdings

AUM $970M
1-Year Est. Return 79.46%
This Fund
S&P 500
This Quarter Est. Return
+26.9%
1 Year Est. Return
+79.46%
3 Year Est. Return
+312.89%
5 Year Est. Return
+648.59%
10 Year Est. Return
–
AUM
$1.05B
AUM Growth
+$91.8M
Cap. Flow
-$24.1M
Cap. Flow %
-2.3%
Top 10 Hldgs %
32.3%
Holding
111
New
20
Increased
23
Reduced
56
Closed
11

Top Buys

Rank Stock Value
1
MASI
Masimo
MASI
+$28.6M
2
DXCM icon
DexCom
DXCM
+$26.9M
3
EYPT icon
EyePoint Inc
EYPT
+$15.4M
4
WAT icon
Waters Corp
WAT
+$15.4M
5
MTD icon
Mettler-Toledo International
MTD
+$15.3M

Top Sells

Rank Stock Value
1
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$17.7M
2
BIIB icon
Biogen
BIIB
+$15.5M
3
DHR icon
Danaher
DHR
+$11.4M
4
CSTL icon
Castle Biosciences
CSTL
+$10.5M
5
VRDN icon
Viridian Therapeutics
VRDN
+$10M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ADPT icon
51
Adaptive Biotechnologies
ADPT
$4.02B
$6.52M 0.62%
+401,730
New +$6.56M
BIIB icon
52
Biogen
BIIB
$30.9B
$6.23M 0.59%
35,425
-94,740
-73% -$15.5M
QURE icon
53
uniQure
QURE
$3.13B
$6.16M 0.59%
257,382
-87,974
-25% -$3.39M
DAWN
54
DELISTED
Day One Biopharmaceuticals
DAWN
$6.02M 0.57%
645,544
+343,798
+114% +$2.87M
IMNM icon
55
Immunome
IMNM
$3.17B
$5.97M 0.57%
277,812
-73,319
-21% -$1.29M
CSTL icon
56
Castle Biosciences
CSTL
$960M
$5.86M 0.56%
150,558
-325,010
-68% -$10.5M
ATEC icon
57
Alphatec Holdings
ATEC
$1.49B
$5.83M 0.56%
277,181
-419,799
-60% -$7.77M
TMDX icon
58
Transmedics
TMDX
$3.02B
$5.5M 0.52%
+45,174
New +$5.67M
SDGR icon
59
Schrodinger
SDGR
$1.39B
$5.35M 0.51%
298,939
-41,248
-12% -$782K
QDEL icon
60
QuidelOrtho
QDEL
$1.02B
$5.27M 0.5%
184,491
-68,326
-27% -$1.85M
CDNA icon
61
CareDx
CDNA
$2.45B
$5.2M 0.5%
+276,154
New +$4.63M
WGS icon
62
GeneDx Holdings
WGS
$2.46B
$5.11M 0.49%
39,272
-5,978
-13% -$821K
VERA icon
63
Vera Therapeutics
VERA
$2.16B
$5.09M 0.48%
100,564
+3,827
+4% +$136K
ABSI icon
64
Absci
ABSI
$1.61B
$5.09M 0.48%
+1,458,652
New +$5.32M
AMLX icon
65
Amylyx Pharmaceuticals
AMLX
$2.6B
$4.61M 0.44%
381,760
-197,414
-34% -$2.68M
NSPR icon
66
InspireMD
NSPR
$40.3M
$4.3M 0.41%
2,416,518
-24,115
-1% -$50.3K
VCYT icon
67
Veracyte
VCYT
$3.59B
$4.22M 0.4%
100,269
-122,796
-55% -$4.95M
PGEN icon
68
Precigen
PGEN
$2.45B
$4.19M 0.4%
1,002,826
-1,098,889
-52% -$4.25M
SYRE icon
69
Spyre Therapeutics
SYRE
$9.18B
$4.08M 0.39%
124,485
-76,268
-38% -$1.99M
URGN icon
70
UroGen Pharma
URGN
$2.39B
$3.95M 0.38%
168,768
-233,827
-58% -$5.07M
ALGN icon
71
Align Technology
ALGN
$12.4B
$3.95M 0.38%
+25,285
New +$3.62M
GPCR icon
72
Structure Therapeutics
GPCR
$3.83B
$3.83M 0.36%
+55,000
New +$2.25M
FDMT icon
73
4D Molecular Therapeutics
FDMT
$621M
$3.78M 0.36%
503,431
+303,431
+152% +$3.08M
RXST icon
74
RxSight
RXST
$294M
$3.66M 0.35%
351,655
-29,058
-8% -$292K
ADMA icon
75
ADMA Biologics
ADMA
$2.19B
$3.65M 0.35%
+200,000
New +$3.37M
1 2
3
4 5

Similar funds

LOIM
Liberty One Investment Management Libertyville, Illinois $970M AUM 12.15% 1-Year Est. Return
MGCM
Mane Global Capital Management New York $971M AUM 58.5% 1-Year Est. Return
JWM
Jackson Wealth Management Lake Mary, Florida $972M AUM 22.58% 1-Year Est. Return
WAM
WNY Asset Management Williamsville, New York $967M AUM
GHC
Graham Holdings Company Arlington, Virginia $967M AUM 15.12% 1-Year Est. Return
SAM
Stansberry Asset Management Westlake, Texas $973M AUM 21.39% 1-Year Est. Return
TCCM
Two Creeks Capital Management New York $974M AUM 2.54% 1-Year Est. Return
UIC
Uniplan Investment Counsel Milwaukee, Wisconsin $974M AUM 21.37% 1-Year Est. Return

Parkman Healthcare Partners's Q4 2025 Portfolio in Review

As of Q4 2025, Parkman Healthcare Partners held 111 positions worth $1.05B, up 9.6% from $959M the previous quarter. Its ten largest holdings account for 32% of the portfolio.

Parkman Healthcare Partners's Q4 2025 filing shows 20 new, 23 increased, 56 reduced and 11 closed positions. Its largest new stake was Masimo: 200,000 shares worth $26M. The largest sale was Alnylam Pharmaceuticals, an estimated $17.7M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 95% a quarter earlier.

  • Parkman Healthcare Partners's largest Q4 2025 buy was Masimo: 200,000 shares worth $26M.
  • Parkman Healthcare Partners added most to DexCom in Q4 2025, an estimated $26.9M increase.
  • Parkman Healthcare Partners's biggest Q4 2025 reduction was Alnylam Pharmaceuticals, cutting an estimated $17.7M.
  • Parkman Healthcare Partners fully exited United Therapeutics in Q4 2025, selling an estimated $9.22M.
  • Parkman Healthcare Partners's ten largest holdings make up 32% of its $1.05B portfolio in Q4 2025.
  • Parkman Healthcare Partners opened 20 new positions and closed 11 in Q4 2025.
  • Parkman Healthcare Partners's portfolio value rose 9.6% quarter-over-quarter to $1.05B.

Based on Parkman Healthcare Partners's 13F filing for Q4 2025, filed 17 Feb 2026.